Lynn L. Bergeson Will Speak During the NanoEHS Workshop Series Webinar
Bergeson & Campbell, P.C. (B&C), B&C Consortia Management, L.L.C. (BCCM), The Acta Group, L.L.C. (Acta), and The Acta Group EU, Ltd (Acta EU) are pleased to announce that on October 20, 2011, from 12:00 p.m. to 12:45 p.m. (EDT), Lynn L. Bergeson will speak during the nanoEHS Workshop Series webinar hosted by the National Nanotechnology Initiative (NNI) on the release of its 2011 Environmental, Health, and Safety Research Strategy (Strategy). The event will consist of an overview of the Strategy’s development followed by comments from industrial, regulatory, and public health perspectives. John Howard, Ph.D., Nanotechnology Environmental and Health Implications (NEHI) Working Group Co-Chair, will serve as the moderator. Panelists include:
- Lynn L. Bergeson, Esquire, Bergeson & Campbell, P.C.;
- Janet Carter, Ph.D., Occupational Safety and Health Administration;
- Shaun F. Clancy, Ph.D., Evonik Degussa Corporation; and
- Treye A. Thomas, Ph.D., NEHI Working Group Co-Chair.
The webinar will also feature a 20-minute question-and-answer segment following the presentations. Questions may be submitted prior to the webinar to firstname.lastname@example.org beginning at 12:00 p.m. (EDT) Wednesday, October 19, 2011, and will be accepted until the close of the webinar at 12:45 p.m.
The official 2011 Environmental, Health, and Safety Research Strategy will be released the day of the webinar and posted by 10:00 a.m. (EDT) online. The previously released draft of the Strategy will remain available for viewing online until the official Strategy is posted. Additional information on how to register is available online.
About Bergeson & Campbell, P.C. — Located in Washington, D.C., B&C is a law firm focusing on conventional and nanoscale industrial, agricultural, and specialty chemical product regulation and approval matters, including Toxic Substances Control Act (TSCA) matters, Federal Insecticide, Fungicide and Rodenticide Act (FIFRA)/Food Quality Protection Act (FQPA) matters, U.S. Food and Drug Administration (FDA) medical device and product approval, registration and data compensation arbitrations, chemical product litigation, and associated business counseling and litigation issues. B&C’s clients are involved in many businesses, including conventional and nanoscale basic, specialty, and agricultural and antimicrobial chemicals; biotechnology, nanotechnology, and emerging transformative technologies; consumer products; medical devices and diagnostic products; paints and coatings; and plastic products. Additional information is available at www.lawbc.com.
About B&C Consortia Management, L.L.C. — BCCM, an affiliate of B&C, has strong institutional experience in consortia management. BCCM provides cost effective administrative and management services to consortia to ensure their interests are protected and their voices heard on issues of concern. BCCM works with industry groups to develop or expand advocacy and/or product stewardship programs, to develop and conduct communications outreach to local, state, federal, or international government entities, to formulate and initiate research programs — whether voluntary or in response to regulatory requirements, and many other activities. Additional information is available at www.bc-cm.com.
About The Acta Group, L.L.C. and The Acta Group EU, Ltd — Acta and Acta EU are consulting affiliates of B&C, established to control the spiraling costs and inefficiencies encountered by clients seeking approvals to market agricultural and industrial chemicals, products of biotechnology and nanotechnology, and Food and Drug Administration-regulated products. Acta and Acta EU manage products from concept to approval, utilizing the skills and experience of professionals who have worked in the specific product areas in government and industry. Additional information is available at www.actagroup.com.